McKesson Corporation (MCK) is well-poised for growth in the coming quarters, courtesy of its strong Biologics business. The optimism led by a solid fourth-quarter fiscal 2024 performance and improving demand for healthcare are expected to contribute further. However, stiff competition and weaker generic pharmaceutical pricing trends persist.Over the past year, this Zacks Rank #3 (Hold) stock has rallied 41.4%.The renowned health care services and information technology company has a market capitalization of ...

文章核心观点 - 公司在最新交易会话中收盘价为575.23美元,较前一交易日下跌1.98%,低于标普500指数0.88%的跌幅 [1] - 公司股价在过去一个月内上涨0.35%,优于医疗行业下跌1.09%,但低于标普500指数5.11%的涨幅 [2] - 公司预计将于2024年8月7日发布财报,预计每股收益为7.16美元,同比下降1.51%;预计收入为833.6亿美元,同比增长11.92% [3] - 全年来看,公司预计每股收益为31.47美元,同比增长14.69%;预计收入为3548亿美元,同比增长14.84% [4] - 分析师对公司的预测有所下调,但公司仍保持Zacks Rank 3(Hold)评级 [5][6][7] - 公司估值方面,其市盈率为18.65,高于行业平均水平17.91;PEG比率为1.38,低于行业平均1.96 [8][9] - 公司所属医疗-牙科用品行业目前在250多个行业中排名前35% [10][11]

McKesson (MCK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this prescription drug distributor have returned +7.3%, compared to the Zacks S&P 500 composite's +3.4% change. During this period, the Zacks Medical - Dental Supplies industry, which McKesson falls in, has gained 1.2%. The key question now is: What could be the stock's future direction?Althou ...

McKesson (MCK) closed the most recent trading day at $599.56, moving -0.8% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 0.16% for the day. Elsewhere, the Dow gained 0.04%, while the tech-heavy Nasdaq added 0.49%.The prescription drug distributor's shares have seen an increase of 10.04% over the last month, surpassing the Medical sector's gain of 2.32% and the S&P 500's gain of 3.22%.Analysts and investors alike will be keeping a close eye on the performa ...

Shares of McKesson Corporation (MCK) scaled a new 52-week high of $605.33 on Jun 20, 2024, before closing the session slightly lower at $603.24.Over the past year, this Zacks Rank #3 (Hold) stock has gained 44.2% compared with 0.9% growth of the industry and the 24.8% rise of the S&P 500 Composite.Over the past five years, the company registered earnings growth of 14.7% compared with the industry’s 12.9% rise. The company’s long-term expected growth rate of 13.6% compares with the industry’s growth projecti ...

In the latest market close, McKesson (MCK) reached $603.24, with a +0.05% movement compared to the previous day. The stock outpaced the S&P 500's daily loss of 0.25%. Meanwhile, the Dow gained 0.77%, and the Nasdaq, a tech-heavy index, lost 0.79%.Coming into today, shares of the prescription drug distributor had gained 8.17% in the past month. In that same time, the Medical sector gained 0.03%, while the S&P 500 gained 3.59%.The upcoming earnings release of McKesson will be of great interest to investors. I ...

McKesson Corporation’s (MCK) Biologics by McKesson, its independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Accord BioPharma, Inc. as an exclusive specialty pharmacy provider for CAMCEVI (leuprolide) 42mg injection emulsion for subcutaneous use. CAMCEVI is a gonadotropin-releasing hormone (GnRH) agonist indicated for the treatment of adult patients with advanced prostate cancer.CAMCEVI was approved by the FDA on May 25, 2021.The availability of the FDA-approv ...

In the latest market close, McKesson (MCK) reached $589.95, with a -0.19% movement compared to the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.04%. Meanwhile, the Dow experienced a drop of 0.15%, and the technology-dominated Nasdaq saw an increase of 0.12%.Heading into today, shares of the prescription drug distributor had gained 6.35% over the past month, outpacing the Medical sector's gain of 2.3% and the S&P 500's gain of 4.15% in that time.Market participants will be ...

McKesson (MCK) closed the most recent trading day at $591.07, moving +1.07% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.23%. At the same time, the Dow lost 0.17%, and the tech-heavy Nasdaq gained 0.34%.The prescription drug distributor's stock has climbed by 6.02% in the past month, exceeding the Medical sector's gain of 2.69% and the S&P 500's gain of 3.96%.Analysts and investors alike will be keeping a close eye on the performance of McKesson in its upcoming earning ...

McKesson (MCK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this prescription drug distributor have returned +6%, compared to the Zacks S&P 500 composite's +4% change. During this period, the Zacks Medical - Dental Supplies industry, which McKesson falls in, has lost 0.6%. The key question now is: What could be the stock's future direction?While media ...